Project Grant R21AI196913
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Leland Stanford Junior University a $423,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. The award supports research investigating how oxygen and bile acid processing influence the small intestinal microbiome and colonization resistance. The research will utilize non-invasive sampling...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Leland Stanford Junior University a Project Grant of $771,210 under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 19, 2026, with a completion date of January 31, 2031. This research initiative will be conducted in Palo Alto, California, and focuses on elucidating the molecular mechanisms by which Salmonella enterica serovar Typhimurium (STM)...
- Federal Project Grant Award Summary The Leland Stanford Junior University received a $153,512 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 13, 2025 through June 30, 2026. This award supports research characterizing the renal immune microenvironment in antibody-mediated rejection (ABMR) using imaging mass cytometry to improve treatment response prediction. The...
- Federal Grant Award Summary Stanford University received a $423,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 25, 2025, with completion targeted for June 30, 2027. This research project investigates antimicrobial peptides and antibiotic diffusion in sputum to address treatment challenges in cystic fibrosis (CF) patients. The research focuses on understanding how...
- Federal Grant Award Summary The National Center for Complementary and Integrative Health (NCCIH) awarded a Project Grant of $787,346 to The Leland Stanford Junior University on April 13, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The research, conducted in Palo Alto, California, and scheduled for completion by December 31, 2030, addresses the restoration of key microbial functions in industrialized gut microbiomes. The project focuses...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $241,500 Project Grant to the University of California, Davis on August 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research project, which extends through July 31, 2027, focuses on accelerating microbiota recovery to protect against Clostridioides difficile infection, a CDC-classified urgent health threat. The investigator-initiated research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $131,076 Project Grant to The Leland Stanford Junior University on August 4, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research titled "Towards a Functional Understanding of Genotypic and Phenotypic Diversity Across the Salmonella Species." The research will be conducted in Palo Alto, California, with a completion date of July 31, 2027. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $160,448 Project Grant to The Leland Stanford Junior University on February 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research extending through August 31, 2028. The research will develop covalent activity-based probes (ABPs) targeting bacterial D,D-carboxypeptidases as a novel theranostic tool for imaging and treating bacterial otitis media...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $151,040 to The Leland Stanford Junior University on February 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports investigator-initiated biomedical research addressing infectious diseases, allergic conditions, and immunologic disorders through the project period ending September 17, 2028. The funded research focuses...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Leland Stanford Junior University a $809,250 Project Grant on April 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance induced pluripotent stem cell (iPSC)-derived thymic epithelial cell (TEC) therapies for T cell immune reconstitution. The research aims to develop regenerative thymic tissues that can restore immune function in vulnerable...
The Leland Stanford Junior University received a $434,090 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026, through March 31, 2028. This research initiative investigates the role of low-abundance microbial species in gut colonization resistance and their contribution to microbiome stability against Clostridioides difficile infection (CDI). The project deliverables include systematic evaluation of low-abundance species' metabolic functions and ecological roles using synthetic microbial communities, metabolomics analysis, and gnotobiotic mouse models to characterize how these species directly compete with C. difficile pathogens and reinforce community resilience following antibiotic-induced perturbations. The research addresses limitations of current microbiome-based therapeutic strategies, such as fecal microbiota transplants (FMTs), by developing improved defined microbial consortia for CDI treatment. Deliverables encompass characterization of metabolic niches and functional redundancies of low-abundance species within the MHCOM (modular human commensal) synthetic community framework and determination of their specific roles in microbiome recovery and C. difficile suppression. These findings are expected to advance scientific understanding of microbiome assembly and contribute to development of more efficacious, reproducible, and clinically applicable microbiome-based therapeutics for CDI management.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $434.1k | 4/1/26 |